Literature DB >> 18981876

Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models.

R Mark Richardson1, Paul S Larson, Krystof S Bankiewicz.   

Abstract

Significant progress has been achieved in developing restorative neurosurgical strategies for movement disorders on the basis of preclinical gene and cell therapy experiments in primates. Because of the unique similarities between human and primate anatomy and physiology, experiments in primate models are the critical step in translating these innovative neurosurgical treatment concepts into successful human applications. To clarify progress toward this goal, we have examined recent preclinical data regarding the delivery of gene and cell therapy to the lesioned primate striatum. Improved behavioral outcomes after in vivo gene transduction, achieved by brain delivery of adeno-associated vectors, have resulted in the initiation of ongoing clinical trials. Cell transplantation experiments are transitioning from the grafting of fetal tissue, which has met with mixed clinical success, to the grafting of expanded neural stem cells, for which preliminary results in primates are encouraging. Careful attention to the surgical delivery parameters for these agents in primate studies, along with the ability to realistically model imaging and behavioral outcomes in these animals, is essential for optimizing the restoration of function for patients. The authors review data obtained from primate models that form the basis for ongoing clinical trials to consider how new preclinical models should be developed to answer questions that arise from experimental clinical data.

Entities:  

Mesh:

Year:  2008        PMID: 18981876     DOI: 10.1227/01.NEU.0000325491.89984.CE

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

1.  Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.

Authors:  R Mark Richardson; Adrian P Kells; Alastair J Martin; Paul S Larson; Philip A Starr; Peter G Piferi; Geoffrey Bates; Lisa Tansey; Kathryn H Rosenbluth; John R Bringas; Mitchel S Berger; Krystof S Bankiewicz
Journal:  Stereotact Funct Neurosurg       Date:  2011-04-14       Impact factor: 1.875

2.  Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.

Authors:  Dali Yin; Francisco E Valles; Massimo S Fiandaca; John Bringas; Francisco Gimenez; Mitchel S Berger; John Forsayeth; Krystof S Bankiewicz
Journal:  Neuroimage       Date:  2009-09-15       Impact factor: 6.556

Review 3.  Convection-enhanced delivery in the treatment of epilepsy.

Authors:  Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 4.  Future applications: gene therapy.

Authors:  R M Richardson; V Varenika; J R Forsayeth; K S Bankiewicz
Journal:  Neurosurg Clin N Am       Date:  2009-04       Impact factor: 2.509

5.  Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.

Authors:  D Yin; Y Zhai; H E Gruber; C E Ibanez; J M Robbins; A P Kells; N Kasahara; J Forsayeth; D J Jolly; K S Bankiewicz
Journal:  Cancer Gene Ther       Date:  2013-05-24       Impact factor: 5.987

Review 6.  Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery.

Authors:  Gurwattan S Miranpuri; Lauren Kumbier; Angelica Hinchman; Dominic Schomberg; Anyi Wang; Hope Marshall; Ken Kubota; Chris Ross; Karl Sillay
Journal:  Ann Neurosci       Date:  2012-07

Review 7.  Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease.

Authors:  R Mark Richardson; Krystof S Bankiewicz; Chadwick W Christine; Amber D Van Laar; Robert E Gross; Russell Lonser; Stewart A Factor; Sandra K Kostyk; Adrian P Kells; Bernard Ravina; Paul S Larson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-07-30       Impact factor: 10.154

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.